September 16, 2020
Natera Inc. pushed back Wednesday against Illumina Inc.'s assertions that Natera's patent covering fetal DNA testing technology for detecting Down syndrome was invalid in light of the prior art, contending that Illumina raised an argument during the remote hearing before the Patent Trial and Appeal Board that wasn't in its petition.